Antitrust Antitrust

Juno, Natco, Celgene withdraw Australian antitrust authorization request for patent settlement

By Laurel Henning
  • 29 Jul 2022 05:27
  • 29 Jul 2022 05:27
Bristol Myers Squibb subsidiary Celgene, along with Australia’s Juno and India’s Natco Pharma, have withdrawn an application for Australia’s competition regulator to authorize the companies’ patent-settlement deal.

In a letter today to the Australian Competition & Consumer Commission, or ACCC, the companies withdrew the application with immediate effect, giving no explanation for

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News